Table 3.

Demographic, clinical, and COVID-related factors associated with disease activity scores^*

	Univariable model			Multivariable model
	β	95% CI	p value	β	95% CI	p value
Age	0.027	0.0097–0.045	0.003	0.023	0.0029–0.043	0.03
Sex	−0.65	−1.8–0.50	0.3	−1.6	−3.0– −0.25	0.02
Race/ethnicity
Hispanic vs Black	0.86	−0.030–1.8	0.06	0.48	−0.50–1.5	0.3
White vs Black	−0.72	−2.4–0.99	0.4	−0.53	−2.4–1.4	0.6
Other vs Black	0.71	−0.67–2.1	0.3	0.28	−1.2–1.8	0.7
Unknown vs Black	−0.24	−1.5–1.0	0.7	−0.84	−2.3–0.63	0.3
SES	−0.11	−0.25–0.036	0.1	−0.075	−0.23–0.083	0.4
Rheumatologic disease
RA vs SLE	0.55	−0.42–1.5	0.3	1.2	0.13–2.4	0.03
Other vs SLE	−0.065	−1.1–0.93	0.9	0.56	−0.61–1.7	0.4
COVID-positive	0.93	−0.64–2.5	0.2	--	--	--
COVID-hospitalized	2.1	−0.69–4.8	0.1	1.2	−1.7–4.2	0.4
High COVID distress	1.6	0.68–2.5	0.001	1.2	0.24–2.1	0.01
Medication access difficulty	2.3	1.3–3.3	<0.001	1.5	0.31–2.8	0.02
Medication interruption	1.6	0.53–2.7	0.004	0.85	−0.47–2.2	0.2

^*N=271 with complete disease activity scores.

High COVID distress was defined as scoring in the upper quartile of the COVID-related distress question. Medication access difficulty and medication interruption were defined as difficulty obtaining a prescribed medication and an interruption in prescribed medication therapy, respectively. Disease activity scores were rated by participants on a scale of 0–10 where 0 was no activity and 10 was the most activity.